• People banner

    People

Caroline Young

Partner

Caroline advises clients on a wide range of commercial matters, specialising in intellectual property and technology.

caroline-young

About

Caroline specialises in commercial contracts, with a particular focus on technology and intellectual property. She works with clients across a broad range of sectors, from TMT and FinTech to life sciences, retail and insurance. Caroline has considerable experience working on the commercialisation of IP and a broad range of technology contracts, including complex licensing and distribution models, development, support and other IT services agreements, IP strategies and exploitation, procurement and outsourcing. Caroline also advises on data protection, consumer law and e-commerce.

Caroline is admitted to practise in England and Wales. 

Experience

  • Advised Hong Kong-listed Symphony Holdings Limited on the $28 million disposal of its Pony international footwear brand, in part to Iconix Brand Group and in part to a new joint venture between Symphony and Iconix.
  • Advising clients in the retail, finance and real estate markets on their respective digital transformation projects; assisting with drafting and strategy throughout the various phases of the project lifecycle, from analysis, scope and design to build and implementation.
  • Drafting research and development agreements, involving complex IP allocation advice, in international drug discovery and development collaborations.
  • Advising on major long-term NHS contracts for provision of our client’s full-service document management services, which incorporated a critical subcontracting arrangement with a leading supplier of electronic document management software for the healthcare industry.
  • Drafting a complex outsourcing agreement for the global roll-out of a new mobile voice recording solution for our investment bank client, and advising on the associated regulations.
  • Drafting services agreements for our charity client in connection with its collaboration with major insurance companies, on a worldwide scale, for implementation of its proprietary health technology targeted at type 2 diabetes sufferers. 
  • Drafting complex licence agreements regarding an extensive patent portfolio (relating to waste gasification technology) for a government funded institution, linking the licensing arrangements to enforcement of security, providing strategic advice on royalty arrangements, and formulating valuation methodologies.

Recognition

  • uk-next-generation-partner-2024

Our thinking

  • Charles Russell Speechlys advises Atkins on the sale of its Scandinavian engineering Services business to Systra

    David Coates

    News

  • Charles Russell Speechlys kickstarts its 'In-House Insights' programme with the first event of the series

    Megan Paul

    News

  • AI and Big Data continue to shape the future of life sciences, but what challenges do we face?

    Caroline Young

    Quick Reads

  • Charles Russell Speechlys advises the discoverIE Group on its acquisition of the CDT Group

    Mike Barrington

    News

  • Charles Russell Speechlys has advised the shareholders of In Touch Games on its sale to Skywind

    Hamish Perry

    News

  • Charles Russell Speechlys acts for Maitland Medical Services Ltd on its acquisition of Soma Health Limited

    Helen Coward

    News

  • Charles Russell Speechlys has advised long-standing client Stonegate on a series A investment into Peckwater Brands

    David Coates

    News

  • Charles Russell Speechlys advises FairXchange on investment from United Fintech

    Charlie Ring

    News

  • Charles Russell Speechlys acts for Cmostores Group Limited on its acquisition of JTM Plumbing Limited

    Caroline Young

    News

  • Charles Russell Speechlys advises discoverIE on its acquisition of Antenova

    Mark Howard

    News

  • Charles Russell Speechlys advises Apollo Aerospace Components on acquisition of NYK Component Solutions

    Daniel Rosenberg

    News

  • Charles Russell Speechlys advises Fudco Partnership on sale to Exponent-backed Vibrant Foods

    James Broadhurst

    News

  • Charles Russell Speechlys advises Emergex Vaccines on $11m fundraising

    Caroline Young

    News

  • Charles Russell Speechlys advise the shareholders of Veriton Pharma on its sale to SERB

    Mark Howard

    News

Back to top